Evidence map›Paper›PMID 39967360›Full record

ArticleEquine veterinary journal2025

Effect of pergolide treatment on insulin dysregulation in horses and ponies with pituitary pars intermedia dysfunction.

Nicolas C Galinelli, Nicholas J Bamford, Madison L Erdody, Skye A Mackenzie, Tobias Warnken, Patricia A Harris, Martin N Sillence, Simon R Bailey

Abstract readRandomized Controlled Trial, Veterinary
PubMed Full text at PMC Publisher
In one paragraph

Article in Equine veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nicolas C GalinelliMelbourne Veterinary School, The University of Melbourne, Parkville, Victoria, Australia.ORCID https://orcid.org/0000-0002-5915-1159
Nicholas J BamfordMelbourne Veterinary School, The University of Melbourne, Parkville, Victoria, Australia.ORCID https://orcid.org/0000-0001-7675-9126
Madison L ErdodyMelbourne Veterinary School, The University of Melbourne, Parkville, Victoria, Australia.
Skye A MackenzieMelbourne Veterinary School, The University of Melbourne, Parkville, Victoria, Australia.
Tobias WarnkenBoehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.ORCID https://orcid.org/0000-0002-0741-4674
Patricia A HarrisEquine Studies Group, Waltham Petcare Science Institute, Melton Mowbray, UK.ORCID https://orcid.org/0000-0003-4068-1624
Martin N SillenceSchool of Biology and Environmental Science, Queensland University of Technology, Brisbane, Queensland, Australia.ORCID https://orcid.org/0000-0003-2837-5456
Simon R BaileyMelbourne Veterinary School, The University of Melbourne, Parkville, Victoria, Australia.ORCID https://orcid.org/0000-0001-9348-5497

Funding

Australian Research Council LP180101000Boehringer IngelheimWaltham Centre for Pet Nutrition
6 · The paper itself

Abstract

backgroundDue to the high frequency of laminitis reported for both conditions, the relationship between pituitary pars intermedia dysfunction (PPID) and insulin dysregulation (ID), and the potential role of dopamine in modifying insulin secretion, requires further investigation.

objectivesTo evaluate the effect of pergolide mesylate on insulin sensitivity and postprandial insulin and glucose responses in horses and ponies with ID, both with or without concurrent PPID. STUDY

designRandomised crossover study.

methodsSixteen horses and ponies, comprising eight matched pairs (PPID+ID or ID-only), were given pergolide mesylate at a dose of 2 μg/kg bwt orally once daily for 4 weeks (plus a 4-week non-treatment control period, with a 4-week washout between phases). A combined glucose and insulin tolerance test (CGIT) and a standard meal test (SMT; containing 1.1 g/kg bwt of starch and 0.1 g/kg bwt of free sugars), were performed before and after each treatment period to determine insulin sensitivity and postprandial insulin and glucose responses, respectively. Variables derived from the CGIT and SMT were analysed using linear mixed models.

resultsPergolide treatment did not alter any of the variables derived from the CGIT in either the PPID+ID or ID-only groups (all p > 0.05). For the SMT, insulin responses were reduced by pergolide treatment for the PPID+ID group, with Δ change values for the total area under the curve for insulin over 300 mins (estimated marginal mean [95% confidence interval]) being -25.4 (-39.9 to -7.3) min∙mIU/mL (p = 0.03) and Δ change values for peak insulin concentration being -100 (-167 to -29) μIU/mL (p = 0.04). No effect of pergolide treatment was detected for the ID-only group. MAIN LIMITATIONS: Number of animals and heterogeneity among groups.

conclusionsPergolide had no effect on tissue insulin sensitivity. However, the results suggest that postprandial hyperinsulinaemia may be limited by this dopamine receptor agonist in animals with PPID plus ID.

Indexed as

Dopamine AgonistsHorse DiseasesInsulinPergolidePituitary DiseasesPituitary Gland, IntermediateAnimalsBlood GlucoseCross-Over StudiesFemaleHorsesInsulin ResistanceMaleBlood GlucoseDopamine AgonistsInsulinPergolidedopamineendocrinehorsehyperinsulinaemiainsulin resistancelaminitis

Identifiers

PMID39967360
PMCPMC12508286

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.